The patients' data examined in this study were from the collective of the 5-FU/FA versus 5-FU/FA/irinotecan
phase III FOGT-4 trial. Tumor tissues were stained by immunohistochemistry for VEGF-C, VEGF-D, VEGFR-3, Hif-1 α, PTEN,
AREG and EREG expression and evaluated by two independent, blinded investigators.
Survival analyses were calculated for all patients receiving adjuvant chemotherapy in relation to expression of all
makers above.